Reblozyl®▼ website is only intended for healthcare professionals in Belgium and Luxembourg.

Reblozyl® (luspatercept) has received European Medicines Agency approval. The registration status and approved product labels of Reblozyl® may vary from country to country.

IMPORTANT: The information on this website is based on the EU Summary of Product Characteristics (SmPC). View the SmPC: in English, in French, in Dutch.

The information provided on this website is intended for use by a healthcare professional qualified to prescribe and supply medications, thus requiring specific scientific knowledge and training to interpret it correctly.

Please authenticate as a qualified healthcare professional.

Or

Alternatively, sign up for emails and access.

If you have any other queries, please contact us via email at medicalaffairs.belgium@bms.com.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See Section 4.8 in the EU Summary of Product Characteristics for more information. Before prescribing Reblozyl®, please refer to the SmPC.

Report an Adverse Event

The safe use of medicines is of the utmost importance.
To report Adverse reactions and suspected or confirmed pregnancy or fetal exposure, please contact us via one of the following methods:

  • E-mail: dsbelgium@bms.com
  • Tel. : +32 (0) 2 352 76 11
  • Post to: Bristol Myers Squibb, Parc de l’Alliance, Avenue de Finlande 4, 1420 Braine-L’Alleud, Belgium

For Belgium:

Additionally, Healthcare professionals in Belgium are asked to report side effects to the Vigilance Department of the Federal Agency for Medicines and Health Products (FAMHP), preferably via their website www.notifieruneffetindesirable.be.

Alternatively, you can use the “yellow paper sheet” which is available on request from the FAMHP or can be printed from www.fagg.be. The completed yellow form should be sent to the FAMHP via one of the following methods:

  • E-mail to: adr@fagg-afmps.be
  • Fax: 02 528 40 01
  • Post to: AFMPS, Division Vigilance, Avenue Galilée 5/03, 1210 Bruxelles.

For Luxembourg:

Reports of adverse events can be sent to the Center Régional de Pharmacovigilance de Nancy via one of the following methods:

  • Email: crpv@chru-nancy.fr
  • Tel: (+33) 3 83 65 60 85/87
  • Post to: Center Régional de Pharmacovigilance de Nancy, Bâtiment de Biologie Moléculaire et de Biopathologie (BBB), CHRU de Nancy – Hôpitaux de Brabois, Rue du Morvan, 54 511 Vandoeuvre les Nancy Cedex, France.

Or send your report to the Direction de la Santé, Division de la Pharmacie et des Médicaments via one of the following methods:

Complaints and fight against counterfeiting

If you have any complaints or if you suspect that your medicine has been counterfeited, please email: medicalinfo.belgium@bms.com

Visit the site for HCPs in: